Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 16, 2001
Grant Date -
N/A
app pub date -
Oct 8, 1997
filing date -
Oct 8, 1997
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention features non-human transgenic animal models for Alzheimer's disease (AD) and CAA, wherein the transgenic animal is characterized by 1) overexpression of bioactive transforming growth factor-.beta.1 (TGF-.beta.1) or 2) both overexpression of bioactive TGF-.beta.1 and expression of a human amyloid .beta. precursor protein (APP) gene product. The transgenic animals may be either homozygous or heterozygous for these alterations. Bigenic animals are further characterized by development of AD-associated and/or CAA-associated pathology within about two to three months of age.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully